Here's how NATURE.COM makes money* and how much!

*Please read our disclaimer before using our estimates.
Loading...

NATURE . COM {}

  1. Analyzed Page
  2. Matching Content Categories
  3. CMS
  4. Monthly Traffic Estimate
  5. How Does Nature.com Make Money
  6. How Much Does Nature.com Make
  7. Keywords
  8. Topics
  9. Questions
  10. Schema
  11. Social Networks
  12. External Links
  13. Analytics And Tracking
  14. Libraries
  15. Hosting Providers
  16. CDN Services

We are analyzing https://www.nature.com/articles/35082500.

Title:
Specific protection against breast cancers by cyclin D1 ablation | Nature
Description:
Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu–Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu–Ras pathways.
Website Age:
30 years and 10 months (reg. 1994-08-11).

Matching Content Categories {📚}

  • Education
  • Telecommunications
  • Health & Fitness

Content Management System {📝}

What CMS is nature.com built with?

Custom-built

No common CMS systems were detected on Nature.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of nature.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month


Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Nature.com Make Money? {💸}


Display Ads {🎯}


The website utilizes display ads within its content to generate revenue. Check the next section for further revenue estimates.

Ads are managed by yourbow.com. Particular relationships are as follows:

Direct Advertisers (10)
google.com, pmc.com, doceree.com, yourbow.com, audienciad.com, onlinemediasolutions.com, advibe.media, aps.amazon.com, getmediamx.com, onomagic.com

Reseller Advertisers (38)
conversantmedia.com, rubiconproject.com, pubmatic.com, appnexus.com, openx.com, smartadserver.com, lijit.com, sharethrough.com, video.unrulymedia.com, google.com, yahoo.com, triplelift.com, onetag.com, sonobi.com, contextweb.com, 33across.com, indexexchange.com, media.net, themediagrid.com, adform.com, richaudience.com, sovrn.com, improvedigital.com, freewheel.tv, smaato.com, yieldmo.com, amxrtb.com, adyoulike.com, adpone.com, criteo.com, smilewanted.com, 152media.info, e-planning.net, smartyads.com, loopme.com, opera.com, mediafuse.com, betweendigital.com

How Much Does Nature.com Make? {💰}


Display Ads {🎯}

$63,100 per month
Our calculations suggest that Nature.com earns between $42,042 and $115,616 monthly online from display advertisements.

Keywords {🔍}

article, cyclin, cas, google, scholar, cancer, nature, breast, cell, access, mice, content, mammary, pathway, genes, cookies, sicinski, oncogene, biol, privacy, cancers, ras, human, open, expression, transgenic, data, specific, geng, gene, cells, transformation, activated, cdk, overexpression, pubmed, development, leder, research, advertising, protection, information, journal, subscribe, piotr, lacking, targeting, neu, institution, buy,

Topics {✒️}

nature portfolio permissions reprints research progress privacy policy advertising g1/s-promoting mechanism parallel social media nature med author information authors yan geng & piotr sicinski core cell-cycle machinery mammary gland development nature 369 nature 398 nature 384 nature 411 nature dana-farber cancer institute mmtv/v-ha-ras author correspondence beta-catenin regulates expression pbabe-puro-ras-v12 fsh-responsive gene involved cyclin d1-deficient mice dfci/harvard medical school mmtv/c-myc genes anti-cyclin d1 therapy beta-casein gene expression e2f-dependent signaling pathway personal data springerlink instant access data protection cell-cycle machinery permissions activated neu–ras pathways human breast cancer breast cancer therapy mammary epithelial cells activated c-neu oncogene breast cancer detected cyclin d1 ablation hc11 cell line harvard medical school privacy development situ breast carcinomas gonadal cell proliferation ras signaling pathway cyclin d1 expression p38/hogmapk pathway

Questions {❓}

  • Are all cancer genes equal?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:Specific protection against breast cancers by cyclin D1 ablation
         description:Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu–Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu–Ras pathways.
         datePublished:
         dateModified:
         pageStart:1017
         pageEnd:1021
         sameAs:https://doi.org/10.1038/35082500
         keywords:
            Science
            Humanities and Social Sciences
            multidisciplinary
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig1_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig2_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig3_HTML.jpg
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig4_HTML.jpg
         isPartOf:
            name:Nature
            issn:
               1476-4687
               0028-0836
            volumeNumber:411
            type:
               Periodical
               PublicationVolume
         publisher:
            name:Nature Publishing Group UK
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Qunyan Yu
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard Medical School
                     address:
                        name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yan Geng
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard Medical School
                     address:
                        name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Piotr Sicinski
               affiliation:
                     name:Dana-Farber Cancer Institute, Harvard Medical School
                     address:
                        name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:
         hasPart:
            isAccessibleForFree:
            cssSelector:.main-content
            type:WebPageElement
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:Specific protection against breast cancers by cyclin D1 ablation
      description:Breast cancer is the most common malignancy among women. Most of these cancers overexpress cyclin D1, a component of the core cell-cycle machinery. We previously generated mice lacking cyclin D1 using gene targeting. Here we report that these cyclin D1-deficient mice are resistant to breast cancers induced by the neu and ras oncogenes. However, animals lacking cyclin D1 remain fully sensitive to other oncogenic pathways of the mammary epithelium, such as those driven by c-myc or Wnt-1. Our analyses revealed that, in mammary epithelial cells, the Neu–Ras pathway is connected to the cell-cycle machinery by cyclin D1, explaining the absolute dependency on cyclin D1 for malignant transformation in this tissue. Our results suggest that an anti-cyclin D1 therapy might be highly specific in treating human breast cancers with activated Neu–Ras pathways.
      datePublished:
      dateModified:
      pageStart:1017
      pageEnd:1021
      sameAs:https://doi.org/10.1038/35082500
      keywords:
         Science
         Humanities and Social Sciences
         multidisciplinary
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig1_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig2_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig3_HTML.jpg
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1038%2F35082500/MediaObjects/41586_2001_Article_BF35082500_Fig4_HTML.jpg
      isPartOf:
         name:Nature
         issn:
            1476-4687
            0028-0836
         volumeNumber:411
         type:
            Periodical
            PublicationVolume
      publisher:
         name:Nature Publishing Group UK
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Qunyan Yu
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yan Geng
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Piotr Sicinski
            affiliation:
                  name:Dana-Farber Cancer Institute, Harvard Medical School
                  address:
                     name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:
      hasPart:
         isAccessibleForFree:
         cssSelector:.main-content
         type:WebPageElement
["Periodical","PublicationVolume"]:
      name:Nature
      issn:
         1476-4687
         0028-0836
      volumeNumber:411
Organization:
      name:Nature Publishing Group UK
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
      name:Dana-Farber Cancer Institute, Harvard Medical School
      address:
         name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Qunyan Yu
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Yan Geng
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      name:Piotr Sicinski
      affiliation:
            name:Dana-Farber Cancer Institute, Harvard Medical School
            address:
               name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
      name:Department of Cancer Biology, and Department of Pathology, Dana-Farber Cancer Institute, Harvard Medical School, Boston, USA
WebPageElement:
      isAccessibleForFree:
      cssSelector:.main-content

External Links {🔗}(83)

Analytics and Tracking {📊}

  • Google Tag Manager

Libraries {📚}

  • Prism.js
  • Zoom.js

Emails and Hosting {✉️}

Mail Servers:

  • mxa-002c5801.gslb.pphosted.com
  • mxb-002c5801.gslb.pphosted.com

Name Servers:

  • pdns1.ultradns.net
  • pdns2.ultradns.net
  • pdns3.ultradns.org
  • pdns4.ultradns.org
  • pdns5.ultradns.info
  • pdns6.ultradns.co.uk

CDN Services {📦}

  • Crossref

3.76s.